编者按代谢功能障碍相关脂肪性肝病（MASLD）及代谢功能障碍相关脂肪性肝炎（MASH）是全球范围内日趋严重的健康问题。肝脏作为人体的代谢中心，通过整合来自胃肠道和脂肪组织的信号，调节碳水化合物、脂质和氨基酸的代谢。然而，肥胖、胰岛素抵抗和2型糖尿病等 ...

The invasive nature of lipid biopsies has lead researchers to dedicate more efforts to unveiling noninvasive diagnostic ...

Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH) is a disease that occurs when ...

该成果为 MASH 研究提供新视角，值得科研人员一读。 在当今社会，代谢综合征引发的肝脏问题日益受到关注。代谢功能障碍相关的脂肪性肝病（MASLD，曾被称为非酒精性脂肪性肝病 NAFLD），就像一颗 “定时炸弹”，在全球范围内威胁着人们的健康。据估计 ...

Metabolic-dysfunction-associated steatotic liver disease (MASLD) arises from excessive intrahepatic triglyceride accumulation ...

近期，一项由中国研究团队开展的多中心、随机、双盲、安慰剂对照研究取得重要成果。该研究表明维生素E疗法能显著增强代谢功能障碍相关脂肪性肝炎（MASH）患者的肝脏功能，减少炎症，为对抗代谢性肝脏疾病提供了更安全有效的治疗选择。这一成果对于MASH患者而言 ...

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.

Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025Denifanstat received Breakthrough Therapy ...

THR-beta agonists are the only medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe form of liver disease. Learn more.

Explore SGMT's breakthrough MASH therapy, Denifanstat, with FDA designation & Phase 3 progress. Click here to read my most ...

FASCINIT in patients with suspected or confirmed diagnosis of MASLD/MASH: The trial is expected to evaluate the safety and efficacy of denifanstat in this population, with the primary endpoint of ...